logo
Adios, Adobe Acrobat. Hello, UPDF.

Adios, Adobe Acrobat. Hello, UPDF.

Yahoo20-06-2025

PDFs have long been the digital equivalent of a necessary chore: tedious, clunky, and often frustrating. But UPDF 2.0 flips the script, turning document work into something surprisingly smooth and efficient, and you don't have to pay a monthly subscription to get it. Right now, lifetime access to UPDF is just $59.99, a sharp 60 percent discount from the usual $149.99.
Heads up: this deal is only for new users, and if you're eyeing UPDF's futuristic AI add-on, that's not included in the lifetime package—you'll have to grab it separately from UPDF.com.
Now for the good stuff. UPDF runs seamlessly across Windows, macOS, iOS, and Android, so whether you're on your laptop, phone, or tablet, your PDFs are always within reach. And UPDF isn't just a PDF reader; it's a powerful editor that lets you tweak text and images right inside your files. Whether for business or personal use, you can convert PDFs to Word, Excel, PowerPoint, HTML, or images—and vice versa.
Need to merge, split, reorder pages, or watermark your documents? No problem. Plus, you can annotate, highlight, and password-protect your work with ease. It packs all the features you expect from Adobe Acrobat—but without the bloated subscription model.
The AI features are where UPDF really gets next-level. Imagine chatting with your PDFs, automatically summarizing long reports, translating on the fly, or even creating mind maps from dense documents. Just remember, these AI powers require a separate purchase.
For tech-savvy guys juggling contracts, research, or side gigs, UPDF offers serious bang for your buck. It's a clean, versatile tool with a one-time fee and lifetime updates—no recurring charges, no fuss. Simply put, it's grown-up PDF management with style and substance.
Get a lifetime subscription to UPDF and edit, convert, and use AI chat with PDFs for $59.99 (reg. $149.99).
StackSocial prices subject to change.
_
UPDF – Edit, Convert, AI Chat with PDF: Lifetime Subscription
See Deal

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Citi Maintains ‘Neutral' Rating on EchoStar Corporation (SATS); Raises PT
Citi Maintains ‘Neutral' Rating on EchoStar Corporation (SATS); Raises PT

Yahoo

time30 minutes ago

  • Yahoo

Citi Maintains ‘Neutral' Rating on EchoStar Corporation (SATS); Raises PT

EchoStar Corporation (NASDAQ:SATS) is one of the best stocks for a . The corporate headquarters of a satellite radio systems company, illuminating the skyline. As announced on June 24, 2025, Citi maintained a 'Neutral' rating on EchoStar Corporation (NASDAQ:SATS), raising its price target from $27 to $28.50. The analyst cited its reevaluation of EchoStar's potential value related to its spectrum assets. These assets include the company's licenses for radio frequencies used for communication. Furthermore, Citi expects a strategic update to be announced by the company within 30 days. The analyst highlights its importance as this expected development would come at a critical time, as EchoStar approaches a bond-related interest payment milestone. EchoStar Corporation (NASDAQ:SATS), a U.S.-based telecommunications company, delivers broadband, wireless, and satellite services through its Pay-TV, Retail Wireless, and BSS segments, and is also part of our growth stock portfolio. While we acknowledge the potential of SATS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: 10 Overlooked Tech Stocks to Buy Now and 10 Low Risk High Reward Stocks Set to Triple by 2030. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BMO Capital Maintains ‘Outperform' Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT
BMO Capital Maintains ‘Outperform' Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT

Yahoo

time30 minutes ago

  • Yahoo

BMO Capital Maintains ‘Outperform' Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the best stocks added in a . A well-stocked pharmacy shelf full of the company's pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products. BMO Capital maintained an 'Outperform' rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), announcing this on June 24, 2025. The analyst raised its price target on the company's stock from $300 to $360. BMO Capital attributed this update to a drastic increase in Amvuttra sales for ATTR-CM, according to IQVIA tracking data, after the drug's approval in March. Furthermore, the analyst cited the continued consistency of the company's sales trends, reinforcing confidence in its commercial traction. While short-term skepticism exists regarding the company's revenue growth, Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) consistent historical trend of revenue and pipeline growth supports its potential for continued growth. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a biopharmaceutical company, develops and markets RNAi therapeutics for rare and genetic diseases. The company has demonstrated consistent YoY revenue growth, making it part of the growth stock portfolio. While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: 10 Best Marketing Stocks to Buy Right Now and 10 Best Cybersecurity Stocks to Invest in Under $20. Disclosure: None.

Key Senators Strike Deal To Pause State AI Laws For Five Years
Key Senators Strike Deal To Pause State AI Laws For Five Years

Bloomberg

time38 minutes ago

  • Bloomberg

Key Senators Strike Deal To Pause State AI Laws For Five Years

The Senate is poised to approve a controversial provision preventing some US states from regulating artificial intelligence, marking a victory for the tech companies, venture capital firms and startups that backed it. The language, which is part of President Donald Trump's signature tax legislation, had drawn opposition from a handful of Republican senators who derided the provision as a giveaway to the biggest tech companies.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store